Evidence map›Paper›PMID 40522994›Full record

ArticlePLoS pathogens2025

PHD3-VHL axis controls HIV-2 infection through oxygen-dependent hydroxylation and degradation of Vpx.

Kei Miyakawa, Kiho Tanaka, Yoko Ino, Yayoi Kimura, Taichi Kameya, Fuminori Mizukoshi, Mayuko Nishi, Masaru Yokoyama, Jun Nakabayashi, Masako Nomaguchi and 9 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kei MiyakawaAIDS Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.ORCID 0000-0002-2219-6839
Kiho TanakaDepartment of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan.
Yoko InoAdvanced Medical Research Center, Yokohama City University, Yokohama, Japan.
Yayoi KimuraAdvanced Medical Research Center, Yokohama City University, Yokohama, Japan.
Taichi KameyaDepartment of Bioinformatics and Integrative Omics, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Fuminori MizukoshiDepartment of Bioinformatics and Integrative Omics, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Mayuko NishiDepartment of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan.
Masaru YokoyamaDepartment of Bioinformatics and Integrative Omics, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Jun NakabayashiInstitute of Liberal Arts, Institute of Science Tokyo, Ichikawa, Japan.
Masako NomaguchiDepartment of Microbiology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Hironori SatoDepartment of Bioinformatics and Integrative Omics, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Hirokazu KimuraDepartment of Health Science, Graduate School of Health Sciences, Gunma Paz University, Takasaki, Japan.
Hirofumi AkariCenter for the Evolutionary Origins of Human Behavior, Kyoto University, Inuyama, Japan.
Tomoyuki MiuraInstitute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Akinori TakaokaDivision of Signaling in Cancer and Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
Hideki HasegawaInfluenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Tetsuro MatanoAIDS Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Yoji Andrew MinamishimaDepartment of Biochemistry, Gunma University Graduate School of Medicine, Maebashi, Japan.
Akihide RyoDepartment of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan.

Funding

Japan Agency for Medical Research and DevelopmentJapan Society for the Promotion of ScienceYokohama Foundation for the Advancement of Medical Science
6 · The paper itself

Abstract

HIV-2 viral protein X (Vpx) plays a pivotal role in antagonizing the host restriction factors, including SAMHD1 and components of the HUSH complex, to facilitate viral replication. However, the regulatory mechanisms controlling Vpx stability remain unclear. In this study, we identify the von Hippel-Lindau (VHL) tumor suppressor as a novel E3 ubiquitin ligase that specifically targets Vpx for proteasomal degradation. Mechanistically, we demonstrate that VHL-mediated degradation depends on the oxygen-dependent hydroxylation of Vpx at proline residue 41 (Pro41), a modification catalyzed by prolyl hydroxylase domain-containing protein 3 (PHD3). Using an integrated approach combining crosslinking mass spectrometry and molecular modeling analyses, we elucidate the structural architecture of the PHD3-Vpx complex, revealing the spatial orientation of the catalytic domain of PHD3 required for Pro41 hydroxylation. Furthermore, we establish the physiological significance of this pathway in human macrophages, where pharmacological inhibition or genetic ablation of VHL or PHD3 enhances HIV-2 infection by facilitating Vpx-mediated SAMHD1 degradation. Collectively, our findings unveil a previously unrecognized oxygen-sensitive regulatory mechanism influencing HIV-2 infection and suggest novel therapeutic strategies targeting Vpx stability through modulation of its prolyl hydroxylation status.

Indexed as

HIV-2HIV InfectionsHypoxia-Inducible Factor-Proline DioxygenasesViral Regulatory and Accessory ProteinsVon Hippel-Lindau Tumor Suppressor ProteinHEK293 CellsHumansHydroxylationMacrophagesOxygenProteolysisHypoxia-Inducible Factor-Proline DioxygenasesOxygenVHL protein, humanViral Regulatory and Accessory ProteinsVon Hippel-Lindau Tumor Suppressor ProteinVPX protein, Human immunodeficiency virus 2

Identifiers

PMID40522994
PMCPMC12201638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.